Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 12/20 | 0.74 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.74 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472155 | 0.90 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL29416842 | 0.90 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL29398203 | 0.90 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL31280899 | 0.89 | NTSR1 (0.74) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL29357887 | 0.89 | OPRD1 (0.63) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL29353193 | 0.89 | OPRD1 (0.63) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL30880437 | 0.88 | NTSR1 (0.82) | NTSR1NTSR2SORT1 | |
| SCHEMBL30999858 | 0.87 | NTSR1 (0.62) | NTSR1NTSR2SORT1OPRD1OPRM1 | |
| SCHEMBL30431861 | 0.87 | NTSR1 (0.61) | NTSR1NTSR2SORT1 | |
| SCHEMBL29725007 | 0.87 | NTSR2 (0.71) | NTSR1NTSR2SORT1OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583825-B2 | Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer | Redona Therapeutics, Inc. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4698529-A1 | BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4698528-A1 | SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250388567-A1 | SELECTIVE G PROTEIN-COUPLED RECEPTOR KINASE 5 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250346587-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC DERIVATIVES AS CHECKPOINT KINASE 1 INHIBITOR AND USES THEREOF | SPEROGENIX THERAPEUTICS LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-12435059-B2 | AMP-activated protein kinase inhibitors and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4554944-A2 | KINASE INHIBITORS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025097025-A1 | PROTEIN KINASE C (PKC) THETA INHIBITOR COMPOUNDS | EVOMMUNE, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-113227054-B | ROCK kinase inhibitors | 切尔韦洛治疗有限责任公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-4532492-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC DERIVATIVES AS CHECKPOINT KINASE 1 INHIBITOR AND USES THEREOF | Sperogenix Therapeutics Limited (HK) | 2025-04-09 | — | — | EP | disclosed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-114380798-A | Salts of Pim kinase inhibitors | 因赛特公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | Cervello Therapeutics LLC (US) | 2022-04-21 | — | — | US | disclosed |
| WO-2022074143-A1 | BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER | Basilea Pharmaceutica International AG (CH) | 2022-04-14 | — | — | WO | disclosed |
| EP-3347351-B1 | SALTS OF A PIM KINASE INHIBITOR | INCYTE CORP (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11278541-B2 | Low dose combination therapy for treatment of myeloproliferative neoplasms | INCYTE CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| CN-114222747-A | PIM kinase inhibitor composition and application thereof | 斯奈普生物公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3962916-A1 | PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF | Snap Bio, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-108715590-B | Thiazolecarboxamide and picolinamide compounds useful as PIM kinase inhibitors | 因赛特公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388567-A1 | SELECTIVE G PROTEIN-COUPLED RECEPTOR KINASE 5 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | GRK5, GRK3, GRK2 | NTSR1 952/4885NTSR2 1141/4885SORT1 4420/4885 |
| US-20250346587-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC DERIVATIVES AS CHECKPOINT KINASE 1 INHIBITOR AND USES THEREOF | CHEK1, CHEK2, BUB1 | NTSR1 3382/4885NTSR2 3850/4885SORT1 4852/4885 |
| US-11278541-B2 | Low dose combination therapy for treatment of myeloproliferative neoplasms | PIM1, JAK2, JAK1 | NTSR1 2687/4885NTSR2 3301/4885SORT1 4442/4885 |
| US-12435059-B2 | AMP-activated protein kinase inhibitors and methods of making and using the same | PRKAA1, PRKAA2, PRKAG1 | NTSR1 3608/4885NTSR2 3179/4885SORT1 4365/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | NTSR1 3870/4885NTSR2 3323/4885SORT1 4826/4885 |
| US-12583825-B2 | Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer | H1-3, RB1, H1-2 | NTSR1 473/4885NTSR2 533/4885SORT1 4882/4885 |
| US-20220119406-A1 | SUBSTITUTED ISOQUINOLINES AS ROCK KINASE INHIBITORS | ROCK1, ROCK2, CIT | NTSR1 3765/4885NTSR2 3243/4885SORT1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.